Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 13/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10304818 | 0.82 | TSHR (0.45) | TSHRNISCHSOS1ARALDH1A1 | |
| SCHEMBL23563886 | 0.80 | TSHR (0.43) | TSHRNISCHSOS1ARALDH1A1 | |
| SCHEMBL3974692 | 0.79 | TSHR (0.44) | TSHRARALDH1A1L3MBTL1 | |
| SCHEMBL16957796 | 0.78 | TSHR (0.42) | TSHRNISCHSOS1ARALDH1A1 | |
| SCHEMBL29946019 | 0.78 | TSHR (0.42) | TSHRNISCHSOS1ARALDH1A1 | |
| SCHEMBL27349177 | 0.78 | TSHR (0.42) | TSHRNISCHSOS1ARALDH1A1 | |
| SCHEMBL23526257 | 0.78 | TSHR (0.42) | TSHRNISCHSOS1ARALDH1A1 | |
| SCHEMBL23526260 | 0.78 | TSHR (0.42) | TSHRNISCHSOS1ARALDH1A1 | |
| SCHEMBL30014022 | 0.78 | TSHR (0.42) | TSHRNISCHSOS1ARALDH1A1 | |
| SCHEMBL819145 | 0.78 | TSHR (0.59) | TSHRNISCHARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | US | claimed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-9751843-B2 | Substituted uracils and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20160297771-A1 | SUBSTITUTED URACILS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-13 | — | — | US | disclosed |
| CN-105980381-A | Substituted uracils and use thereof | 拜耳医药股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-3066098-A1 | SUBSTITUTED URACILS AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067630-A1 | SUBSTITUTED URACILS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | TYMP, PNP, CD4 | TSHR 4499/4885NISCH 3532/4885SOS1 3507/4885 |
| US-20160297771-A1 | SUBSTITUTED URACILS AND USE THEREOF | UNG, UMPS, TYMP | TSHR 3979/4885NISCH 2077/4885SOS1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.